ELAN Elanco Animal Health Inc
Price (delayed)
$10.04
Market cap
$4.97B
P/E Ratio
14.76
Dividend/share
N/A
EPS
$0.68
Enterprise value
$8.82B
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company,
Highlights
The company's EPS has surged by 127% YoY and by 66% QoQ
Elanco Animal Health's net income has soared by 127% YoY and by 65% from the previous quarter
ELAN's equity is down by 7% from the previous quarter and by 2% YoY
The quick ratio has contracted by 6% YoY and by 2.8% from the previous quarter
Key stats
What are the main financial stats of ELAN
Market
Valuations
Earnings
Shares outstanding
494.61M
Market cap
$4.97B
Enterprise value
$8.82B
Price to earnings (P/E)
14.76
Price to book (P/B)
0.81
Price to sales (P/S)
1.12
EV/EBIT
12.2
EV/EBITDA
6.37
EV/Sales
1.99
Revenue
$4.44B
Gross profit
$2.44B
Operating income
$83M
Net income
$338M
EBIT
$723M
EBITDA
$1.39B
Free cash flow
$460M
Per share
Balance sheet
Liquidity
EPS
$0.68
EPS diluted
$0.68
Free cash flow per share
$0.93
Book value per share
$12.33
Revenue per share
$8.99
TBVPS
$9.15
Total assets
$12.61B
Total liabilities
$6.52B
Debt
$4.32B
Equity
$6.1B
Working capital
$1.9B
Debt to equity
0.71
Current ratio
2.44
Quick ratio
1.03
Net debt/EBITDA
2.78
Margins
Efficiency
Dividend
EBITDA margin
31.2%
Gross margin
54.9%
Net margin
7.6%
Operating margin
1.9%
Return on assets
2.5%
Return on equity
5.5%
Return on invested capital
8.8%
Return on capital employed
6.4%
Return on sales
16.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ELAN stock price
How has the Elanco Animal Health stock price performed over time
Intraday
-7.04%
1 week
-7.04%
1 month
-12.01%
1 year
-37.33%
YTD
-17.09%
QTD
-17.09%
Financial performance
How have Elanco Animal Health's revenue and profit performed over time
Revenue
$4.44B
Gross profit
$2.44B
Operating income
$83M
Net income
$338M
Gross margin
54.9%
Net margin
7.6%
Elanco Animal Health's operating income has soared by 196% from the previous quarter and by 109% YoY
Elanco Animal Health's net income has soared by 127% YoY and by 65% from the previous quarter
The net margin has soared by 127% year-on-year and by 65% since the previous quarter
The company's operating margin has surged by 109% YoY
Growth
What is Elanco Animal Health's growth rate over time
Valuation
What is Elanco Animal Health stock price valuation
P/E
14.76
P/B
0.81
P/S
1.12
EV/EBIT
12.2
EV/EBITDA
6.37
EV/Sales
1.99
The company's EPS has surged by 127% YoY and by 66% QoQ
The price to book (P/B) is 38% lower than the 5-year quarterly average of 1.3 and 33% lower than the last 4 quarters average of 1.2
ELAN's equity is down by 7% from the previous quarter and by 2% YoY
ELAN's P/S is 53% below its 5-year quarterly average of 2.4 and 30% below its last 4 quarters average of 1.6
Efficiency
How efficient is Elanco Animal Health business performance
Elanco Animal Health's ROIC has soared by 188% YoY and by 14% from the previous quarter
The company's return on sales has surged by 178% YoY and by 9% QoQ
Elanco Animal Health's ROE has soared by 130% YoY and by 67% from the previous quarter
The company's return on assets has surged by 130% YoY and by 67% QoQ
Dividends
What is ELAN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ELAN.
Financial health
How did Elanco Animal Health financials performed over time
Elanco Animal Health's total assets is 94% higher than its total liabilities
The company's total liabilities fell by 20% YoY and by 3.6% QoQ
Elanco Animal Health's total assets has decreased by 12% YoY and by 5% QoQ
The debt is 29% smaller than the equity
The debt is down by 25% year-on-year
The debt to equity has declined by 24% year-on-year but it has increased by 6% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.